Despite the failure to generate satisfying clinical outcomes as monotherapy [51], GM-CSF-secreting tumor vaccines function in a synergistic way with immune checkpoint inhibitors (ICIs) such as Ipilimumab (anti-CTLA-4 antibody) in metastatic melanoma by virtue of its mighty immunostimulatory effects [52]. The gene discussed is CTLA4; the disease is neoplasm.